The Centers for Disease Control and Prevention of the United States has deemed extended-spectrum β-lactamases (ESBLs)-producing Enterobacterales and multidrug-resistant (MDR) Pseudomonas aeruginosa as serious threats and carbapenem-resistant (CR) Enterobacterales (CRE) and CR Acinetobacter as urgent threats. Due to the prevalent drug resistance of these strains and lack of antimicrobial alternatives, the treatment of infections caused by these MDR Gram-negative pathogens rely on tigecycline, polymyxins (colistin and polymyxin B) or new β-lactam/β-lactamase inhibitor combinations (such as ceftazidime-avibactam, CAZ/AVI). However, the critically ill patients with antimicrobial infection are associated with high mortality. Hence, the prevalence and optimal therapy for critically ill patients with antimicrobial resistance are worth further study.
ISBN10 : 9782832535929 , ISBN13 : 2832535925
Page Number : 100